Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians
“Over the past year, we have been building awareness around the potential benefits of targeting treatment in the suprachoroidal space and working closely with retinal specialists to present data on this novel approach. These efforts have led to the formation of a group of leading retinal physicians who can provide real-world insights and validate the scientific rationale for our expanding pipeline programs. We are honored and grateful that Drs. Boyer, Brown, Holekamp, Kaiser and Regillo have joined our newly formed
“Clearside’s novel technology platform delivering proprietary pharmacologic agents to the suprachoroidal space may offer innovative new treatment options for our patients. My advisory board colleagues and I look forward to working with the Clearside team as they advance their research and development programs and explore new therapeutic targets,” added
Members of the
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential of the suprachoroidal injection platform and the advancement of Clearside’s research and development programs. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended
Investor and Media Contacts:
Source: Clearside Biomedical, Inc.